Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 641-646

  Yokokawa, Junko ^a   Kanno, Yukiko ^a   Saito, Hironobu ^a   Abe, Kazumichi ^a   Takahashi, Atsushi ^a   Yokokawa, Hirohide ^b   Ohira, Hiromasa ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Autoimmune hepatitis; Azathioprine; Prednisolone; Relapse; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; IMMUNOGLOBULIN; PREDNISOLONE; PROTHROMBIN; URSODEOXYCHOLIC ACID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; UNIVARIATE ANALYSIS;

EID: 79959784072     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00812.x     Document Type: Article

References (15)

1. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-53.
2. Toda G, Zeniya M, Watanabe F etal. Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997; 26: 1207-12.
3. Czaja AJ, Freese DK, American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
4. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-7.
5. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type-1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
6. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-9.
7. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type-1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-7.
8. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-9.
9. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
10. Alvarez F, Berg PA, Bianchi FB etal. International auto-immune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
11. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
12. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
13. Soloway RD, Summerskill WH, Baggenstoss AH etal. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
14. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type-1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
15. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-4.